Letermovir for the compassionate therapeutic use of cytomegalovirus infection.
Lorenz SchubertLisa FiseckerFlorian ThalhammerHeinz BurgmannChristoph SteiningerPublished in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2020)
Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.